Iowa State University Research Foundation, Inc.

The Medical College of Wisconsin, Inc.

University of Texas System

Anumantha G Kanthasamy

Balaraman Kalyanaraman

Vellareddy Anantharam

George A Kraus

Andrew D Ellington

Surya Mallapragada

Balaji Narasimhan

Ross Thyer

Joy Joseph

Manohar John

Gregory Phillips

Thimmasettappa Thippeswamy

Ahmed Abdalla

Nicholas Backes

The present invention generally provides methods and compositions for the treatment of Parkinson's disease and depression and/or anxiety. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA.

L-DOPA microbiome therapy

Provided are aggregate alpha-synuclein specific antibodies as well as fragments, derivatives, and variants thereof as well as method related thereto for the early diagnostic and treatment of Parkinson's Disease and other Lewy body- and Lewy neurite-based diseases. Assays, kits, systems, and nanoparticle encapsulated compositions related to the antibodies or fragments, derivatives, and variants thereof are also disclosed.

Nano-theranostics for Parkinson's disease

The present invention describes novel pharmaceutical compositions and methods for treatment of diseases, disorders, or conditions characterized by recurrent seizures, particularly, epilepsy. According to the invention, compounds which inhibit the activity or expression of non-receptor Fyn tyrosine kinase can prevent activation epileptic pathophysiology and provide protection from and treatment of epilepsy. Particularly preferred is the class of small molecule Fyn kinase inhibitors such as sacaratinib and its prodrugs, derivatives, analogs and the like.

Tyrosine kinase inhibition as a treatment for epilepsy

The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.

Neuroprotection by mitochondria-targeted metformin

Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.

Neuroprotective compounds and their use

The present invention describes novel pharmaceutical compositions and methods for treatment of diseases, disorders, or conditions characterized by dopamine deficiency, including Alzheimer's disease, Parkinson's disease, Tourette's syndrome, schizophrenia, Huntington's disease, symptoms of attention deficit hyperactivity disorder, drug abuse and clinical depression. The treatment of the present invention utilizes PKCd inhibitors that have the dual benefit of increasing the levels of dopamine in the central nervous system while also protecting neuronal cells from neurodegeneration. The method and pharmaceutical compositions can be used to treat diseases, disorders, or conditions associated with neurodegeneration such as Parkinson's disease, Huntingson's disease, Alzheimer's disease, Parkinson's disease, cerebral ischemia, myocardial ischemia, spinal muscular atrophy, multiple sclerosis, AIDS-related encephalitis, HIV-related encephalitis, aging, alopecia, and neurological damage due to stroke, Huntington disease (HD), amyotrophic lateral sclerosis (ALS), cardiovascular diseases, inflammatory diseases, spinal cord trauma, and head injury.

Dual beneficial effect of dopamine enhancing and neuroprotective actions of PKC delta inhibitors for treatment of Parkinson's disease

A method of synthesizing rottlerin analogs is described. The synthesis methods described are the first known method of synthesizing rottlerin analogs from commercially-available materials to produce cost effective analogs. Rottlerin analog structures made by the synthesis methods and methods of use for treating a neurological or inflammatory response mediated by protein kinase C (PKC) are further described.

Design, synthesis and functional characterization of rottlerin analogs

Methods and compositions are provided which inhibit the apoptotic activity associated with oxidative stress in many disease states. According to the invention, inhibition of chemical cleavage of PKC&#x3b4; by caspase-3 results in reduction of apoptosis. Novel peptide inhibitors with the amino acid motif Asp Ile Pro Asp (SEQ ID NO:5) are also disclosed. The peptides are useful as inhibitors of PKC&#x3b4;-mediated apoptosis and oxidative stress, and other diseases regulated by a catalytically active PKC&#x3b4;.

Growing community of inventors

Ames, IA, United States of America

Anumantha G Kanthasamy